{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:58:28Z","timestamp":1772672308174,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.7759\/cureus.104676","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:30:07Z","timestamp":1772670607000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Bimatoprost Intracameral Implant for the Treatment of Glaucoma: A Focused Narrative Review"],"prefix":"10.7759","author":[{"given":"Arham Yahya","family":"Rizwan Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman SR","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, et al.. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017, 5:e1221-e34. 10.1016\/s2214-109x(17)30393-5","journal-title":"Lancet Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11686","article-title":"Epidemiology of glaucoma: the past, present, and predictions for the future","volume":"12","author":"Allison K","year":"2020","unstructured":"Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020, 12:e11686. 10.7759\/cureus.11686","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas JB","year":"2017","unstructured":"Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017, 390:2183-93. 10.1016\/s0140-6736(17)31469-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0681-y","article-title":"The role of intracranial pressure in glaucoma and therapeutic implications","volume":"34","author":"Baneke AJ","year":"2020","unstructured":"Baneke AJ, Aubry J, Viswanathan AC, Plant GT. The role of intracranial pressure in glaucoma and therapeutic implications. Eye (Lond). 2020, 34:178-91. 10.1038\/s41433-019-0681-y","journal-title":"Eye (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.02.016","article-title":"What we have learned from the ocular hypertension treatment study","volume":"189","author":"Gordon MO","year":"2018","unstructured":"Gordon MO, Kass MA. What we have learned from the ocular hypertension treatment study. Am J Ophthalmol. 2018, 189:xxiv-vii. 10.1016\/j.ajo.2018.02.016","journal-title":"Am J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass MA","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al.. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, 120:701-13. 10.1001\/archopht.120.6.701","journal-title":"Arch Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2019.1635456","article-title":"Medication adherence in patients with ocular hypertension or glaucoma","volume":"14","author":"Robin AL","year":"2019","unstructured":"Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Expert Rev Ophthalmol. 2019, 14:199-210. 10.1080\/17469899.2019.1635456","journal-title":"Expert Rev Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.039","article-title":"Patterns of glaucoma medication adherence over four years of follow-up","volume":"122","author":"Newman-Casey PA","year":"2015","unstructured":"Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015, 122:2010-21. 10.1016\/j.ophtha.2015.06.039","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study","volume":"127","author":"Newman-Casey PA","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020, 127:477-83. 10.1016\/j.ophtha.2019.10.022","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S176412","article-title":"Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes","volume":"13","author":"McClelland JF","year":"2019","unstructured":"McClelland JF, Bodle L, Little JA. Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes. Patient Prefer Adherence. 2019, 13:431-9. 10.2147\/PPA.S176412","journal-title":"Patient Prefer Adherence"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The most common barriers to glaucoma medication adherence: a cross-sectional survey","volume":"122","author":"Newman-Casey PA","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015, 122:1308-16. 10.1016\/j.ophtha.2015.03.026","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S264926","article-title":"Improving adherence to topical medication in patients with glaucoma","volume":"15","author":"Tapply I","year":"2021","unstructured":"Tapply I, Broadway DC. Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence. 2021, 15:1477-89. 10.2147\/PPA.S264926","journal-title":"Patient Prefer Adherence"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016597","article-title":"Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis","volume":"98","author":"Tang W","year":"2019","unstructured":"Tang W, Zhang F, Liu K, Duan X. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Medicine (Baltimore). 2019, 98:e16597. 10.1097\/MD.0000000000016597","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li T","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, et al.. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016, 123:129-40. 10.1016\/j.ophtha.2015.09.005","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000009","article-title":"Glaucoma medication adherence among African Americans: program development","volume":"90","author":"Dreer LE","year":"2013","unstructured":"Dreer LE, Girkin CA, Campbell L, Wood A, Gao L, Owsley C. Glaucoma medication adherence among African Americans: program development. Optom Vis Sci. 2013, 90:883-97. 10.1097\/OPX.0000000000000009","journal-title":"Optom Vis Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.833898","article-title":"Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension","volume":"29","author":"Schwartz GF","year":"2013","unstructured":"Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013, 29:1515-22. 10.1185\/03007995.2013.833898","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.11.020","article-title":"Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I\/II clinical trial","volume":"175","author":"Lewis RA","year":"2017","unstructured":"Lewis RA, Christie WC, Day DG, et al.. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I\/II clinical trial. Am J Ophthalmol. 2017, 175:137-47. 10.1016\/j.ajo.2016.11.020","journal-title":"Am J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00527-6","article-title":"Single administration of intracameral bimatoprost implant 10 \u00b5g in patients with open-angle glaucoma or ocular hypertension","volume":"11","author":"Medeiros FA","year":"2022","unstructured":"Medeiros FA, Sheybani A, Shah MM, et al.. Single administration of intracameral bimatoprost implant 10 \u00b5g in patients with open-angle glaucoma or ocular hypertension. Ophthalmol Ther. 2022, 11:1517-37. 10.1007\/s40123-022-00527-6","journal-title":"Ophthalmol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1985145","article-title":"Intracameral sustained release bimatoprost implants (Durysta)","volume":"37","author":"Sirinek PE","year":"2022","unstructured":"Sirinek PE, Lin MM. Intracameral sustained release bimatoprost implants (Durysta). Semin Ophthalmol. 2022, 37:385-90. 10.1080\/08820538.2021.1985145","journal-title":"Semin Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.4.20","article-title":"Nonclinical pharmacokinetic and pharmacodynamic assessment of bimatoprost following a single intracameral injection of sustained-release implants","volume":"9","author":"Shen J","year":"2020","unstructured":"Shen J, Robinson MR, Struble C, Attar M. Nonclinical pharmacokinetic and pharmacodynamic assessment of bimatoprost following a single intracameral injection of sustained-release implants. Transl Vis Sci Technol. 2020, 9:20. 10.1167\/tvst.9.4.20","journal-title":"Transl Vis Sci Technol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0067","article-title":"Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues","volume":"35","author":"Seal JR","year":"2019","unstructured":"Seal JR, Robinson MR, Burke J, Bejanian M, Coote M, Attar M. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Ther. 2019, 35:50-7. 10.1089\/jop.2018.0067","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.018","article-title":"Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1)","volume":"127","author":"Medeiros FA","year":"2020","unstructured":"Medeiros FA, Walters TR, Kolko M, et al.. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020, 127:1627-41. 10.1016\/j.ophtha.2020.06.018","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01624-9","article-title":"Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2)","volume":"81","author":"Bacharach J","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, et al.. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021, 81:2017-33. 10.1007\/s40265-021-01624-9","journal-title":"Drugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01248-0","article-title":"24-month phase I\/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients","volume":"80","author":"Craven ER","year":"2020","unstructured":"Craven ER, Walters T, Christie WC, et al.. 24-month phase I\/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020, 80:167-79. 10.1007\/s40265-019-01248-0","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.12.026","article-title":"Phase 3, randomized, comparison study of intracameral bimatoprost implant 10\u202f\u00b5g and selective laser trabeculoplasty","volume":"272","author":"Kolko M","year":"2025","unstructured":"Kolko M, Tatham AJ, Lim KS, et al.. Phase 3, randomized, comparison study of intracameral bimatoprost implant 10\u202f\u00b5g and selective laser trabeculoplasty. Am J Ophthalmol. 2025, 272:19-37. 10.1016\/j.ajo.2024.12.026","journal-title":"Am J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S445005","article-title":"Real-world study of the effectiveness and safety of intracameral bimatoprost implant in a clinical setting in the united states","volume":"18","author":"Teymoorian S","year":"2024","unstructured":"Teymoorian S, Craven ER, Nguyen L, Werts E.  Real-world study of the effectiveness and safety of intracameral bimatoprost implant in a clinical setting in the united states. Clin Ophthalmol. 2024, 18:187-99. 10.2147\/OPTH.S445005","journal-title":"Clin Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S450220","article-title":"Bimatoprost SR for glaucoma therapy implanted at the slit-lamp in a real-world setting","volume":"18","author":"Ali AA","year":"2024","unstructured":"Ali AA, Avil\u00e9s Elescano D, Grover DS. Bimatoprost SR for glaucoma therapy implanted at the slit-lamp in a real-world setting. Clin Ophthalmol. 2024, 18:1371-7. 10.2147\/OPTH.S450220","journal-title":"Clin Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095461","article-title":"Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation","volume":"9","author":"Franca JR","year":"2014","unstructured":"Franca JR, Foureaux G, Fuscaldi LL, et al.. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation. PLoS One. 2014, 9:e95461. 10.1371\/journal.pone.0095461","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.05.015","article-title":"Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: in vitro and in vivo evaluation","volume":"103","author":"Yadav M","year":"2019","unstructured":"Yadav M, Guzman-Aranguez A, Perez de Lara MJ, Singh M, Singh J, Kaur IP. Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: in vitro and in vivo evaluation. Mater Sci Eng C Mater Biol Appl. 2019, 103:109730. 10.1016\/j.msec.2019.05.015","journal-title":"Mater Sci Eng C Mater Biol Appl"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464410-use-of-bimatoprost-intracameral-implant-for-the-treatment-of-glaucoma-a-focused-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:30:09Z","timestamp":1772670609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464410-use-of-bimatoprost-intracameral-implant-for-the-treatment-of-glaucoma-a-focused-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.104676","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}